期刊
PANCREAS
卷 49, 期 8, 页码 1014-1023出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPA.0000000000001626
关键词
pancreatic cancer; PDAC; immunotherapy; immunogenicity; T cells
资金
- NCI [R01 CA50633]
- National Institutes of Health (NIH)/National Cancer Institute (NCI) [P30-CA051008]
- King Saud bin Abdulaziz University for Health Sciences (KSAU-HS)
- Saudi Arabian Cultural Mission (SACM)
Worldwide, approximately half a million people are diagnosed with pancreatic cancer every year, with mortality rates of more than 90%. T cells within pancreatic tumors are generally infrequent and incapable of eliciting antitumor immunity. Thus, pancreatic cancer is considered an immunologically cold tumor. However, recent studies clearly show that when T-cell immunity in pancreatic cancer is sufficiently induced, T cells become effective weapons. This fact suggests that to improve pancreatic cancer patients' clinical outcomes, we need to unveil the complex immune biology of this disease. In this review, we discuss the elements of tumor immunogenicity in the specific context of pancreatic malignancy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据